Sanofi's BD chief heads to Owkin as CBO; Roche re­lies on its bench for Thomas Schi­neck­er’s di­ag­nos­tics re­place­ment

Up un­til re­cent­ly, Al­ban de La Sablière was Sanofi’s chief deal­mak­er, re­port­ing di­rect­ly to CEO Paul Hud­son with­out of­fi­cial­ly be­ing a C-suite ex­ec­u­tive.

That’s now changed with de La Sablière’s newest po­si­tion at a much small­er French biotech, Sanofi part­ner Owkin. And to top it off, it’s his first job in the C-suite.

Tues­day was his first day as the chief busi­ness of­fi­cer at Owkin, a now-transat­lantic biotech with of­fices in both France and the US. Its em­pha­sis in AI and a con­cept called “fed­er­at­ed learn­ing” earned a $270 mil­lion in­vest­ment from the Big Phar­ma last year, with an eye to im­prov­ing its odds in clin­i­cal de­vel­op­ment. The com­pa­ny has now inked oth­er AI deals with oth­er Big Phar­ma com­pa­nies such as Bris­tol My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER